Management of GVHD in a case of AML with Haploidentical SCT

Publish Year: 1398
نوع سند: مقاله کنفرانسی
زبان: English
View: 313

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

ISMOH18_137

تاریخ نمایه سازی: 8 بهمن 1398

Abstract:

Introduction: Bone marrow transplant is replace healthy bone marrow with unhealthy bone marrow, which is used to treat many diseases that affect one s bone marrow, such as thalassemia and cancer. The common types of transplantation are: - Autologous transplantation: During this transplant the patient receives a transplanted tissue (bone marrow)from himself . - Allogeneic transplantation: The patient receives transplanted tissue from a person other than himself or a similar twin (such as a sister, brother or any parent or person who has no relationship to the patient). - Haploid transplantation: Transplantation from a donor with HlA is semi-similar to pateint, which the donor and recipient immune systems are involved in severe immune responses and cause severe complex effects.Case Report:The patient is a 26-year -old male known case of AML who is a candidate for Haploidentical allogeneic stem cell transplantationBefore Haplo-Hsct planning he received six corse consolidation since one course induction .In complete remission he was selected for Haplo-Hsct because he didn t have FDM. Therefore we decided to choose his sister as a donor with HLA typing 5/10 and ABO miss match.He was admitted in BMT ward of Kermanshah Imam Reza hospital complex with 5 years experience, on Jun-13, 2019 Mobilization of donor cells was preformed with Tina peg amp Conditioning protocol included Busilvex and Cyclophosphamaid chemotherapy regimen At the same time, he received lST with corticosteroids (Hydrocortisone and methylprednisolpn ), Cyclosporine, cellcept.Also he received T cell depletion drugs including Thimoglobulin 150mg/3days (pre transplant) and Endoxan 3gr/2days (post transplant ) He was prophylactically treated with Antifungal (Fluconazol) Antibacterial (Cotrimoxazol) Antiviral (Valgancyclovir) medications. HSCT was done in Jun -20 ,2019.Afrer infusion donor s stem cell he had acute shock syndrome that was controlled by Cortny and fluid therapy.During the transplantation phase he suffered Mocositis and Pharyngitis , who was treated with Caspofongin, mouthwash and Meropenem (1gr /TDS)Also in the neutropenia phase , GCSF was administered to the patientHe had a fever (T=39)on the eleventh days of HSCT who was treated with Linazolide and the dose of Meropenem increased to 2gr/TDS The day after fever , engraftment happened Also he received Hydrocortisone for 48 hours to treat engraftment syndrome. The Coombs(Direct -In direct) test was also checked which was negative.During hospitalization , blood cultures , Urine cultures , Stool cultures and Cmv were checked , fortunately there were no reports of infection.The patient wasdischarged from hospital with oral medication orders including Valgancyclovir, Ursobil , Fluconazol, Cotrimoxazol, Sandimon, Cellcept, Prednisolon(at a dose of 7/5mg/daily) on the seventeenth day transplant.Conclusion: Post-transplantation cyclo-phosphamide regimen (PTCY) and the use of ATG can decrease GVH response and increase GVL. Also, the strategy of using steroids since the beginning of SCT has been effective in reducing GVHD complications

Authors

Mehrdad Payandeh,

Department of Hematology and Medical Oncology,Kermanshah University of Medical Science, Kermanshah , Iran